Pancreatic Cancer Research

ResearcherJichi Medical UniversityActive in the last 2 years

Kazufumi Honda

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-1321-5345; OpenAlex author ID A5026500116, A5102507904. Sources: OpenAlex.

Their work

Papers
20 (first author 3, last author 6)
Trials
0
Grants
0
Labs led
2
Collaborators
77
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: none · 2014: none · 2015: 2 papers · 2016: 2 papers · 2017: 1 paper · 2018: 1 paper · 2019: 2 papers · 2020: 3 papers · 2021: none · 2022: 1 paper · 2023: none · 2024: 2 papers · 2025: 1 paper · 2026: 3 papers

Papers 20

  1. A Case With Longitudinal Changes in Apolipoprotein A2 Isoform Indices Associated With CA19-9 and MRI Findings Until Pancreatic Cancer Development. Co-author DOI 10.1111/jgh.70857↗
  2. ApoA2 isoforms as blood-based biomarkers reflecting pancreatic exocrine dysfunction for risk stratification and perioperative management of pancreatic cancer. Last author DOI 10.3389/fonc.2026.1902440↗
  3. A Pancreatic Ductal Adenocarcinoma Diagnostic System Using Serum Extracellular Vesicle Detection with Optimized Lectin Combination Using Machine Learning. Co-author DOI 10.3390/cancers18060924↗
  4. Platform of single-molecule enzyme activity-based liquid biopsy for detection of pancreatic adenocarcinoma at early stages Co-author DOI 10.1101/2025.08.07.669035↗
  5. Clinical development of a blood biomarker using apolipoprotein-A2 isoforms for early detection of pancreatic cancer. Last author DOI 10.1007/s00535-023-02072-w↗
  6. Identification of TPI1 As a potential therapeutic target in pancreatic cancer with dependency of TP53 mutation using multi-omics analysis. Last author DOI 10.1111/cas.16302↗
  7. Risk stratification of pancreatic cancer by a blood test for apolipoprotein A2-isoforms. Co-author DOI 10.3233/cbm-210198↗
  8. Use of Biomarkers and Imaging for Early Detection of Pancreatic Cancer. First author DOI 10.3390/cancers12071965↗
  9. O-Glycan-Altered Extracellular Vesicles: A Specific Serum Marker Elevated in Pancreatic Cancer. Co-author DOI 10.3390/cancers12092469↗
  10. Prospective Study Using Plasma Apolipoprotein A2-Isoforms to Screen for High-Risk Status of Pancreatic Cancer. Last author DOI 10.3390/cancers12092625↗
  11. CA19-9 and apolipoprotein-A2 isoforms as detection markers for pancreatic cancer: a prospective evaluation. Co-author DOI 10.1002/ijc.31900↗
  12. Trends in biomarker discoveries for the early detection and risk stratification of pancreatic cancer using omics studies First author DOI 10.1080/14737159.2019.1643718↗
  13. Measurement of copy number of ACTN4 to optimize the therapeutic strategy for locally advanced pancreatic cancer. Last author DOI 10.1016/j.pan.2018.06.003↗
  14. Identification of highly sensitive biomarkers that can aid the early detection of pancreatic cancer using GC/MS/MS-based targeted metabolomics. Co-author DOI 10.1016/j.cca.2017.02.011↗
  15. Identification of IGFBP2 and IGFBP3 As Compensatory Biomarkers for CA19-9 in Early-Stage Pancreatic Cancer Using a Combination of Antibody-Based and LC-MS/MS-B… Co-author DOI 10.1371/journal.pone.0161009↗
  16. Potential usefulness of apolipoprotein A2 isoforms for screening and risk stratification of pancreatic cancer. Co-author DOI 10.2217/bmm-2016-0209↗
  17. ACTN4 copy number increase as a predictive biomarker for chemoradiotherapy of locally advanced pancreatic cancer. Last author DOI 10.1038/bjc.2014.623↗
  18. Plasma biomarker for detection of early stage pancreatic cancer and risk factors for pancreatic malignancy using antibodies for apolipoprotein-AII isoforms. Co-author DOI 10.1038/srep15921↗
  19. Altered plasma apolipoprotein modifications in patients with pancreatic cancer: protein characterization and multi-institutional validation. Co-author DOI 10.1371/journal.pone.0046908↗
  20. Reduced plasma level of CXC chemokine ligand 7 in patients with pancreatic cancer. First author DOI 10.1158/1055-9965.epi-10-0397↗

Closest collaborators

The 25 strongest of 77 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ayumi Kashiro · 5 shared papers, 2020–2026 · strength 1.06
  2. Shingo Kato · 3 shared papers, 2020–2024 · strength 0.60
  3. Akira Matsushita · 2 shared papers, 2024–2026 · strength 0.48
  4. Chigusa Morizane · 4 shared papers, 2015–2025 · strength 0.48
  5. Satoshi Nara · 3 shared papers, 2020–2025 · strength 0.43
  6. Susumu Hijioka · 2 shared papers, 2024–2025 · strength 0.36
  7. Takashi Kobayashi · 3 shared papers, 2017–2020 · strength 0.34
  8. Masaki Kuwatani · 1 shared paper, 2026 · strength 0.33
  9. Kazumichi Kawakubo · 1 shared paper, 2026 · strength 0.33
  10. Naoya Sakamoto · 1 shared paper, 2026 · strength 0.33
  11. Ryo Sugiura · 1 shared paper, 2026 · strength 0.33
  12. Sudhir Srivastava · 3 shared papers, 2015–2024 · strength 0.31
  13. Minoru Kitago · 2 shared papers, 2020–2026 · strength 0.31
  14. Atsushi Kuno · 2 shared papers, 2020–2026 · strength 0.31
  15. Yuko Kitagawa · 2 shared papers, 2020–2026 · strength 0.31
  16. Yasuaki Kabe · 2 shared papers, 2020–2026 · strength 0.31
  17. Junji Ueda · 1 shared paper, 2026 · strength 0.27
  18. Mutsuo Furihata · 1 shared paper, 2026 · strength 0.23
  19. Sho Uemura · 1 shared paper, 2026 · strength 0.23
  20. Tatsuya Kawakami · 1 shared paper, 2026 · strength 0.23
  21. Kaoru Furihata · 1 shared paper, 2026 · strength 0.23
  22. Akihiko Tsuchida · 6 shared papers, 2011–2017 · strength 0.21
  23. Tesshi Yamada · 6 shared papers, 2011–2017 · strength 0.21
  24. Takuji Okusaka · 6 shared papers, 2011–2017 · strength 0.21
  25. Hirokazu Shoji · 3 shared papers, 2015–2019 · strength 0.21

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.